We use cookies to improve site performance and enhance your user experience. If you'd like to disable cookies on this device, please see our cookie management page.
If you close this message or continue to use this site, you consent to our use of cookies on this devise in accordance with our cookie policy, unless you disable them.


registration required

for more website access

This content can only be viewed by subscribers and registered users of Investors Chronicle.

Subscribe or register free today

Hikma returns after spring

Branded and generic medicines company Hikma Pharmaceuticals has returned to growth in some of its key Middle Eastern and North Africa (MENA) markets after the disruption caused by the Arab Spring. The improvement meant like-for-like group sales grew by 7.6 per cent and helped maintain adjusted operating profits at $146m (£93m).

registration required

visible-status-Standard story-url-Hikma Full year 2011 14 Mar 2012.xml

By Julian Hofmann,
14 March 2012

Print this article

Related Companies

Advertiser reports

Register today and get...

Register today and get...
Please note terms & conditions apply